|Other Names||Vascular endothelial growth factor D, VEGF-D, c-Fos-induced growth factor, FIGF, FIGF, VEGFD|
|Target/Specificity||The synthetic peptide sequence is selected from aa 337-352 of HUMAN FIGF|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Growth factor active in angiogenesis, lymphangiogenesis and endothelial cell growth, stimulating their proliferation and migration and also has effects on the permeability of blood vessels. May function in the formation of the venous and lymphatic vascular systems during embryogenesis, and also in the maintenance of differentiated lymphatic endothelium in adults. Binds and activates VEGFR-2 (KDR/FLK1) and VEGFR-3 (FLT4) receptors.|
|Tissue Location||Highly expressed in lung, heart, small intestine and fetal lung, and at lower levels in skeletal muscle, colon, and pancreas|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
The protein encoded by this gene is a member of the platelet-derived growth factor/vascular endothelial growth factor (PDGF/VEGF) family and is active in angiogenesis, lymphangiogenesis, and endothelial cell growth. This secreted protein undergoes a complex proteolytic maturation, generating multiple processed forms which bind and activate VEGFR-2 and VEGFR-3 receptors. This protein is structurally and functionally similar to vascular endothelial growth factor C.
Orlandini, M., et al., J. Biol. Chem. 278(45):44650-44656 (2003).
McColl, B.K., et al., J. Exp. Med. 198(6):863-868 (2003).
Rissanen, T.T., et al., Circ. Res. 92(10):1098-1106 (2003).
Nakamura, Y., et al., Clin. Cancer Res. 9(2):716-721 (2003).
Yokoyama, Y., et al., Br. J. Cancer 88(2):237-244 (2003).
If you have any additional inquiries please email technical services at firstname.lastname@example.org.